Bleakley Financial Group LLC Has $6.17 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bleakley Financial Group LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,868 shares of the medical research company’s stock after buying an additional 812 shares during the quarter. Bleakley Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $6,174,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. AMF Tjanstepension AB bought a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $42,409,000. Czech National Bank lifted its holdings in shares of Thermo Fisher Scientific by 7.0% during the 3rd quarter. Czech National Bank now owns 77,816 shares of the medical research company’s stock valued at $48,135,000 after purchasing an additional 5,076 shares in the last quarter. Axiom Advisory LLC increased its stake in Thermo Fisher Scientific by 1.6% during the 3rd quarter. Axiom Advisory LLC now owns 1,216 shares of the medical research company’s stock worth $720,000 after purchasing an additional 19 shares in the last quarter. Atomi Financial Group Inc. boosted its holdings in shares of Thermo Fisher Scientific by 81.3% in the third quarter. Atomi Financial Group Inc. now owns 2,829 shares of the medical research company’s stock valued at $1,750,000 after buying an additional 1,269 shares during the period. Finally, Artemis Investment Management LLP lifted its position in Thermo Fisher Scientific by 103.1% in the 3rd quarter. Artemis Investment Management LLP now owns 16,877 shares of the medical research company’s stock valued at $10,440,000 after acquiring an additional 8,566 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 9,000 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the sale, the chief executive officer now owns 14,608 shares of the company’s stock, valued at $8,076,178.88. This trade represents a 38.12 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,125 shares of company stock valued at $16,207,439. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Bank of America dropped their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. TD Cowen lifted their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. UBS Group lifted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $581.72 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The stock has a market cap of $222.51 billion, a PE ratio of 35.19, a PEG ratio of 4.06 and a beta of 0.77. The firm’s fifty day moving average price is $544.31 and its two-hundred day moving average price is $571.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.